VYGR - MCAP CO - Voyager Therapeutics

Voyager Therapeutics (VYGR) revenue is based on royalties and upfront payments from the licensing of gene correction methods for neuropathologies. Meanwhile, the business adheres to bioethical principles, minimizing the use of chemicals and guaranteeing the protection of patient data. Serving as an assessment tool, this chart of the valuation on GURU.Markets, where the indicator stands at 0.16, confirms the value of unique patents for brain drug delivery, which allow the company to collaborate effectively with global partners.

The integration of ESG principles and bioethics into the development of gene therapies strengthens the market position of Voyager Therapeutics (VYGR). Market capitalization reflects the aggregate value of all the company's shares, calculated based on current quotes. This metric serves as an indicator of the market consensus regarding the business's value. Monitoring this figure allows investors to assess capital preservation over the long term. The price action in this company valuation chart helps identify shifts in the macroeconomic cycle in a timely manner.